Filing Details AIM ImmunoTech Inc. (AMEX:AIM) filed a definitive proxy statement (DEF 14A) with the Securities and Exchange Commission on June 25, 2026. The Healthcare company's…
AIM ImmunoTech Inc. (AMEX:AIM) filed a definitive proxy statement (DEF 14A) with the Securities and Exchange Commission on June 25, 2026.
The Healthcare company's proxy statement provides information for shareholders ahead of the annual meeting, including board nominations, executive compensation, and proposals for shareholder vote.
AIM ImmunoTech Inc.'s stock currently trades at $0.36 with a market capitalization of $3.1M.
SEC filings provide mandatory disclosures that give investors access to the same material information available to institutional investors. Reviewing AIM ImmunoTech Inc.'s filings alongside price action and analyst commentary provides a more complete picture of the company's current situation.
All SEC filings for AIM ImmunoTech Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View AIM Stock Page
Browse all filings on our AIM SEC filings page.
Public companies like AIM ImmunoTech Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.
Current market data
AMEX · AIM
$0.23
Down: -$0.01 · -2.70%
Live quote updated
Keep reading
